Filing Details

Accession Number:
0001140361-17-047821
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-12-29 17:03:01
Reporting Period:
2017-12-29
Accepted Time:
2017-12-29 17:03:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358762 Reata Pharmaceuticals Inc RETA Pharmaceutical Preparations (2834) 113651945
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1372218 Cpmg Inc 2000 Mckinney Ave, Ste 2125
Dallas TX 75201
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2017-12-29 17,000 $28.47 44,200 No 4 P Indirect By Barred Owl Partners, LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Barred Owl Partners, LP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Common Stock 34,897 Indirect By Managed Account for Trustees of the University of Pennsylvania
Class A Common Stock 442,560 Indirect By Gallopavo, LP
Class A Common Stock 748,253 Indirect By Roadrunner Fund, LP
Class A Common Stock 103,185 Indirect By Blackwell Partners LLC
Class A Common Stock 431,155 Indirect By Yellow Warbler, LP
Class A Common Stock 110,640 Indirect By Killdeer Fund, LP
Class A Common Stock 109,415 Indirect By Mallard Fund, LP
Class A Common Stock 280,500 Indirect By Willet Fund, LP
Class A Common Stock 37,909 Indirect By Crested Crane, LP
Class A Common Stock 63,481 Indirect By Flamingo Fund, LP
Class A Common Stock 334,740 Indirect By Sandpiper Fund, LP
Class A Common Stock 160,265 Indirect By Kestrel Fund, LP
Class A Common Stock 11,076 Indirect By CD Fund, LP
Class A Common Stock 134 Indirect By Redbird Life Sciences Partners, LP
Class A Common Stock 113 Direct
Footnotes
  1. This price reflects the weighted average purchase price for open-market purchases on December 29, 2017, within a $1.00 range. The actual prices for these transactions range from $28.40 to $28.50 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
  2. The Reporting Person is the investment manager of each of: Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.